Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Series D

Scalable Capital mounts $58m series D campaign
Scalable Capital is valued in excess of $460m following a round that lifted the digital wealth manager's total funding to about $130m.
Corporates help energise Natron's $35m series D
Sodium-ion battery producer Natron, a Stanford spinout, has picked up corporates ABB and Chevron in a round bringing its lifetime funding to more than $70m.
Evidation Health generates $45m results
McKesson Ventures came onboard for the health data provider Evidation's series D round, helping it hike its overall funding to $106m five years after being co-founded by Stanford Health Care.
XSky stores $45.3m series D
Cloud storage provider XSky pushed its funding haul to $38m after securing the return of a Tsinghua University's fund management affiliate.
Orca Bio organises $192m series D
Kaiser Permanente contributed to a round that pushed the total raised by the Stanford-aligned cellular cancer therapy developer to $300m.
SQZ sequences $65m series D
GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.
New Horizon brings $20m series D
Dumac contributed to a round that took the total raised by the cancer screening system developer past the $130m mark.
Reflexion radios in for another $100m
The radiotherapy developer, which is exploiting UChicago research, has now raised $264m in funding overall.

Other News

Graphcore grows series D to $350m
Graphcore, which traces its origins back to University of Bristol, has added $150m to a round that already included Ahren Innovation Capital.
Verana charts course to $100m
Oak Ridge spinout Verana Health has completed a $100m round led by existing investor GV that will help it expand its clinical database platform into new areas.
Promethera protracts series D round
Medipal and Sony Innovation Fund by IGV were among the investors that boosted the liver disease drug spinout's latest round to $52.6m.
Inscripta cribs $125m in series D round
CU Boulder spinout Inscripta has now accumulated more than $259m from investors including Institut Mérieux, and will use the capital to further expand its genome engineering platform.
Sera Prognostics diagnoses $36m series D
Based on research from Brigham Young University and University of Utah, Sera has added $36m to its funding vault to drive commercialisation of its blood testing system PreTRM.
EpicentRx rustles up $35m
Building on UCSD intellectual property, EpicentRx is working on immunotherapy drugs intended to target the body's non-specific and adaptive specific immune function synchronously.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
test reg